(Q36764876)

16 August 2017

1 reference

title

Inhibiting kinases in malignant gliomas (English)

1 reference

16 August 2017

Andrew S Chi

1

1 reference

PubMed ID

17373878

16 August 2017

Patrick Y Wen

series ordinal

2

1 reference

PubMed ID

17373878

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Therapeutic Targets

16 August 2017

1 reference

16 August 2017

11

1 reference

16 August 2017

4

1 reference

16 August 2017

473-496

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular pathology of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular pathogenesis of astrocytic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Autoinhibition of Bcr-Abl through its SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting the cell cycle: a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Signaling--2000 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Intracellular signal transduction pathway proteins as targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Biology of vascular endothelial growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Mechanisms of angiogenesis in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Type I insulin-like growth factor receptor as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

c-Src and cooperating partners in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Reduced glioma infiltration in Src-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The role of focal-adhesion kinase in cancer - a new therapeutic opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

FAK signaling in anaplastic astrocytoma and glioblastoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Raf kinase as a target for anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Protein kinase C (PKC) family in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting the TGF beta signaling network in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Drug discovery: playing dirty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Combining radiation and molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The emerging normal and disease-related roles of anaplastic lymphoma kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Notch signalling: a simple pathway becomes complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Recent insights into the role of Notch signaling in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

NOTCH signaling as a novel cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

The hedgehog signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Brain as a paradigm of organ growth: Hedgehog-Gli signaling in neural stem cells and brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Morphing into cancer: the role of developmental signaling pathways in brain tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Convection-enhanced delivery of therapeutics for brain disease, and its optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

21 January 2018

Imaging in neurooncology

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Dynamic magnetic resonance perfusion imaging of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular optical imaging: applications leading to the development of present day therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

DNA-microarray analysis of brain cancer: molecular classification for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Identification of molecular subtypes of glioblastoma by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Positive and negative regulation of insulin signaling through IRS-1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Network biology: understanding the cell's functional organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Data-driven modelling of signal-transduction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Applications of mouse glioma models in preclinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Molecular pathways triggering glioma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Neural stem cells and the origin of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.4.473

10.1517/14728222.11.4.473

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17373878